AstraZeneca boss Pascal Soriot’s pay rises to £17.7m

AI Summary
AstraZeneca CEO Pascal Soriot's total compensation rose 6.4% to £17.7m in the past year, driven by a £1.5m salary, £4.3m in bonuses, and £11.6m in share bonuses, reflecting a 32% increase in AstraZeneca's share price and strong financial performance. Despite this, AstraZeneca cancelled a £450m expansion of its vaccine site in Speke and halted a £200m research investment in Cambridge due to a dispute with the government over drug pricing. Soriot is in line for a further pay increase this year, potentially reaching £19.6m. His high pay has previously triggered shareholder rebellions, despite the company's improved financial performance. Since joining AstraZeneca in 2012, Soriot has rebuilt the company's drug pipeline and fended off a takeover bid from Pfizer.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis.
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.